LixiLan-L Study

Lixilan-L study

LixiLan-L Study

Read about the efficacy and safety of Suliqua in this clinical summary of the phase III LixiLan-L study. This study demonstrates the efficacy of Suliqua a titratable fixed-ratio combination of insulin glargine + lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin.
Aroda VR, et al. Diabetes Care. 2016; 39: 1972–80

This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy.
By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.
Accept and close